CELLINK Launches the BIO CELLX, a First of its Kind Biodispensing Platform to Automate 3D Cell Culture
The BIO CELLX provides cell biologist with pre-validated protocols to eliminate barriers for automating 3D cell-based assays targeting cancer research and drug discovery.
Today CELLINK, A BICO Company, launched the BIO CELLX a novel system that automates 3D cell culture workflows by leveraging pre validated protocols. The BIO CELLX builds upon CELLINK’s impressive bioprinting portfolio utilizing proven technologies like the patented Clean Chamber combined with a unique new method for effortless mixing of hydrogels and cells, high precision dispensing and automatic nozzle priming to create a system for reproducible and high throughput model generation.
By introducing the concept of pre-validated protocols, the BIO CELLX provides cell biologists a solution for the development of 3D models without need for coding, CAD modelling or parameter selection and optimization. The BIO CELLX continues to harness the power of bioconvergence through the use of ECM based hydrogels provided by Advanced BioMatrix, another BICO group company.
“This product is an important step in proliferating 3D cell culture and the numerous advantages it can bring to cell biologists. With the BIO CELLX we have developed a solution that effectively empowers researchers to transition to 3D cell culture workflows, providing effective and reproducible models that can truly improve research outcomes,” says Johan Norrman, CTO, CELLINK.
“We are thrilled to be bringing the BIO CELLX to the drug discovery market. For the last 5 years we have developed cutting edge bioprinters and have utilized this expertise to develop an automated biodispensing platform solution that makes the power of 3D accessible to all with easy to understand set up and effortless material and cell mixing. We look forward to enabling the pharma industry with technology which we hope will bring meaningful breakthroughs in cancer research and therapy development by providing biomimetic models,” added Cecilia Edebo, CEO, CELLINK.
The BIO CELLX was selected as a finalist for the New Product Award at the recent SLAS conference in Boston for its potential impact in the market.
Visit www.cellink.com to learn more.
For further information, please contact:
Avijit Minocha, Head of Marketing, BICO
Phone (US): +1 (617) 637 5372
Email: akm@cellink.com
This information was submitted for publication, through the agency of the contact persons set out above, on March, 01, 2022 at 08:00 (CET).
About CELLINK
CELLINK is creating the future of health as part of BICO, the world’s leading bioconvergence company. When CELLINK released the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 700 publications and are trusted by more than 1,000 academic, pharmaceutical and industrial labs. At the forefront of the bioprinting industry, CELLINK aims to alleviate organ donor shortage with biofabricated transplantable organs and remains committed to reducing our dependence on animal testing and increasing efficiencies in drug development with more physiologically relevant bioprinted organ models. Visit www.cellink.com to learn more.
About BICO
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com